Clostridium Infections: all 251 studies

Page 2 of 3. Open to participants first (51), then studies with results posted, then the rest; newest registration first within each.

• Efficacy of Metronidazole Prophylaxis Against Clostridium Difficile-Associated Diarrhea in High Risk Adult PatientsTerminatedNCT02200328Phase 4Results posted
• Alanyl-glutamine Supplementation of Standard Treatment for C. Difficile InfectionTerminatedNCT02053350Phase 2Results posted
• Effect of Acid Suppression Medication on Pediatric MicrobiomeTerminatedNCT02016820Not applicableResults posted
• Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated DiarrheaCompletedNCT01987895Phase 3Results posted
• Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated DiarrheaCompletedNCT01983683Phase 3Results posted
• Molecular Epidemiology of Clostridium Difficile Infections in ChildrenCompletedNCT01957761Results posted
• Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated DiarrheaCompletedNCT01925417Phase 2Results posted
• Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile InfectionTerminatedNCT01887912Phase 3Results posted
• Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus VancomycinCompletedNCT01818141Phase 4Results posted
• Evaluation of the Immune Response to Clostridium Difficile in Adults With Clostridium Difficile Infection (CDI)CompletedNCT01716533Not applicableResults posted
• A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)CompletedNCT01598311Phase 3Results posted
• Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)CompletedNCT01597505Phase 3Results posted
• A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)CompletedNCT01513239Phase 3Results posted
• Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile InfectionCompletedNCT01259726Phase 2Results posted
• A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)CompletedNCT01241552Phase 3Results posted
• Study of CB-183,315 in Participants With Clostridium Difficile InfectionCompletedNCT01085591Phase 2Results posted
• Phase I Randomized, Placebo-Controlled, Double-Blind, Dose Ranging Study, Safety, Tolerability and ImmunogenicityTerminatedNCT00772954Phase 1Results posted
• Hospital Design and Risk of Nosocomial Infections: A Prospective Controlled TrialCompletedNCT00563186Not applicableResults posted
• PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)CompletedNCT00468728Phase 3Results posted
• Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated DiseaseCompletedNCT00350298Phase 2Results posted
• Efficacy and Safety of BIO-K + CL1285 in Prevention of Antibiotic-associated Diarrhea in Hospitalized Adult PatientsCompletedNCT00328263Phase 3Results posted
• Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018)CompletedNCT00314951Phase 3Results posted
• A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)CompletedNCT00269399Phase 3Results posted
• Safety, Tolerability, and Immunogenicity of a Clostridium Difficile Toxoid Vaccine in Healthy Elderly VolunteersCompletedNCT00214461Phase 1Results posted
• Safety, Tolerability, and Immunogenicity Study of a Clostridium Difficile Toxoid Vaccine in Healthy Adult VolunteersCompletedNCT00127803Phase 1Results posted
• Effect of Oral Microbiota on MDRO DecolonizationCompletedNCT07496502Phase 1/2
• Study of Metronidazole Delayed-Release Capsules in Comparison With Immediate-Release Tablets (Flagyl) for Safety and PharmacokineticsCompletedNCT07251127Phase 1
• C. Difficile Toxin Levels in Stool From Healthy Individuals Following Standard of Care Antibiotic Treatment for CDI.Active, not recruitingNCT07250724
• Primary Prophylaxis of Clostridioides Difficile Infection With Oral VancomycinWithdrawnNCT07221708Phase 2/3
• An Open-Label, Pilot Clinical Trial To Test The Safety And Feasibility Of A Suspension of Freeze-dried Microbiota In Patients Undergoing Colon ResectionCompletedNCT06692179Phase 1
• Safety and Tolerability of AZD5148 in Japanese ParticipantsCompletedNCT06639997Phase 1
• A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD5148 in Healthy AdultsCompletedNCT06469151Phase 1
• C.Difficile Observational StudyCompletedNCT06277999
• REBYOTA™ Prospective RegistryCompletedNCT05835219
• Dietary Optimization of Microbiome Recovery Following Fecal Microbiota TransplantationCompletedNCT05826418Not applicable
• The Dynamic Fluctuation of Donor Microbiota Affects the Prognosis of Fecal Microbiota Transplantation for C. Difficile InfectionCompletedNCT05703477Not applicable
• Evaluation of GeoHAI ImplementationActive, not recruitingNCT05612672Not applicable
• Bacillus Velezensis DSM 33864 for Reduction of the Risk of Recurrent Clostridioides Difficile InfectionsWithdrawnNCT05606159Not applicable
• Ursodeoxycholic Acid in C. Difficile InfectionTerminatedNCT05526807Not applicable
• LMN-201 for Prevention of C. Difficile Infection RecurrenceActive, not recruitingNCT05330182Phase 2/3
• Oral Vancomycin Vs Placebo in the Prevention of Recurrence of Clostridioides Difficile's InfectionCompletedNCT05320068Phase 3
• Seroprevalence of Antibodies to Surface Antigens and Toxins of Clostridioides DifficileStatus unknownNCT05192148Not applicable
• Bezlotoxumab Versus FMT for Multiple Recurrent CDIWithdrawnNCT05077085Phase 4
• Creation of an E-toileting Log Through Classification of the Physical Properties of Stool and Urine Using TrueLoo™CompletedNCT05008640
• A Study of ART24 in Subjects Recently Cured of a Clostridioides Difficile Infection (CDI)CompletedNCT04891965Phase 1
• Fecal Microbiota Transplantation for Early Clostridioides Difficile InfectionCompletedNCT04885946Not applicable
• Monoclonal Antibodies in Clostridium Difficile InfectionCompletedNCT04874623Not applicable
• Addressing Personalized Needs in Clostridioides Difficile InfectionCompletedNCT04725123Not applicable
• Establishment of the Human Intestinal and Salivary Microbiota Biobank - Gastrointestinal DiseasesCompletedNCT04698148
• The Role of Mucosal Microbiome in the Development, Clearance and Recurrence of Clostridioides Difficile InfectionWithdrawnNCT04679324
• The Role of Mucosal Microbiome in Recurrence of Clostridioides Difficile InfectionCompletedNCT04675723
• The Characteristics and Role of Mucosal Microbiome After Treatment of Clostridioides Difficile InfectionCompletedNCT04668014
• Clinical Comparison of Treatment Strategies in AmpC Beta-lactamase Producing Enterobacterales in a Swiss Tertiary Care HospitalCompletedNCT04577989
• Clostridioides Difficile Infection - a Prospective Nationwide Epidemiologic Study in KoreaStatus unknownNCT04567134
• Bezlotoxumab Efficacy and Tolerability in Cancer PatientStatus unknownNCT04415918Phase 4
• Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile InfectionCompletedNCT04317963
• PROSPECTIVE STUDY OF PREDISPOSING FACTORS OF REFRACTARY Clostridium Difficile INFECTION. INFLUENCE OF THE GUT MICROBIOMAStatus unknownNCT04259931
• Validation of a Prediction Score for Recurrent C. Difficile Infection: Implementation for Treatment Algorithm StrategiesStatus unknownNCT04187430
• Study on Clostridium Difficile Infection in Chinese Patients With Inflammatory Bowel DiseaseStatus unknownNCT04179201
• Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile InfectionCompletedNCT04138706Phase 3
• Treatment of Mild-moderate Clostridium Difficile Infection (CDI)Status unknownNCT04121169Phase 2
• A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Clostridoides Difficile InfectionWithdrawnNCT04100603
• Fecal Microbiota TransplantCompletedNCT04090346Phase 4
• Bezlotoxumab - in "Real Life" - During the First Episode of Clostridium Difficile Infection in Patients With High Risk of Recurrence.CompletedNCT04075422
• Evaluation of Fidaxomicin in the Treatment of Clostridium Difficile Infection (CDI)WithdrawnNCT04070352
• Protocol for Admission Toxigenic C. Difficile SurveillanceCompletedNCT04014608
• CDI Synbiotic StudyStatus unknownNCT04012788Not applicable
• Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)TerminatedNCT04000555Phase 4
• Specific Carbohydrate Diet for Clostridium DifficileCompletedNCT03925636Not applicable
• C Difficile Near-patient DiagnosticsCompletedNCT03857464Not applicable
• FQ Restriction for the Prevention of CDICompletedNCT03848689
• Vancomycin for the Treatment of NAAT(+)/Toxin(-) C. DifficileCompletedNCT03827447Phase 1
• Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With CDADCompletedNCT03824795Phase 2
• Fecal Microbiota Transplant by Oral Capsules With Lactobacilli for Recurrent Clostridium Difficile InfectionStatus unknownNCT03804736Not applicable
• Fecal Transplantation for Primary Clostridium Difficile InfectionTerminatedNCT03796650Phase 3
• Safety and Efficacy of DAV132 in Patients at High-Risk for Clostridium Difficile Infection (CDI)CompletedNCT03710694Not applicable
• Clostridium Difficile Virulence Mechanism Study (CDVM Study)Status unknownNCT03654872
• Phase II Trial of Fecal Microbiota Transplant (FMT) for VRE and CRE PatientsWithdrawnNCT03643887Phase 2
• Use of Bismuth Subsalicylate in Clostridium Difficile ColitisWithdrawnNCT03592082Phase 4
• Relationship Between C. Difficile Toxins' Serum Level With C. Difficile InfectionStatus unknownNCT03586206
• Oral Vancomycin to Prevent Recurrent C Difficile Infection With AntibioticsCompletedNCT03466502Phase 4
• Fecal Microbiota Transplantation for Severe Clostridium Difficile InfectionCompletedNCT03427229Phase 2
• Prevention of Clostridium Difficile Infections Using Lactobacillus Plantarum 299v StrainStatus unknownNCT03368105Not applicable
• Lyophilized Fecal Transplant vs Lyophilized Fecal Filtrate in Recurrent C Diff InfectionCompletedNCT03353506Phase 2
• A Screening and Recruitment Study in Adults Expressing Interest in the Emory Microbiota Enrichment ProgramSuspendedNCT03350711
• Fecal Microbial Transplantation for C. Difficile and/or Ulcerative Colitis or Indeterminate ColitisCompletedNCT03268213Early Phase 1
• Antibiotic Stewardship and Infection Control in Patients at High Risk of Developing Infection by Clostridium Difficile, Vancomycin-Resistant Enterococci or Multi-Resistant Gram-NegativesCompletedNCT03250104
• Effectiveness of Isolating Clostridium Difficile Asymptomatic Carriers on the Incidence of InfectionsCompletedNCT03223415Not applicable
• Oral Vancomycin for Preventing Clostridium Difficile RecurrenceTerminatedNCT03200093Phase 4
• Incidence and Economic Burden of Clostridium Difficile Infections (CDI) in the German Health Care System (IBIS)Status unknownNCT03141775
• Fecal Microbiota Transplantation (FMT) in Clostridium Difficile Infection (CDI) Not Responding to AntibioticsCompletedNCT03117582
• Treatment of Initial Clostridium Difficile InfectionCompletedNCT03107169Not applicable
• Treatment for Clostridium-difficile Infection With IMM529TerminatedNCT03065374Phase 1/2
• A Novel Faecal Microbiota Transplantation System for Treatment of Primary and Recurrent Clostridium Difficile InfectionStatus unknownNCT03053505Not applicable
• Evaluation of the Cost of a Nosocomial Infection With Clostridium DifficileCompletedNCT03025672
• Oral Vaccination Against Clostridium Difficile InfectionTerminatedNCT02991417Phase 1
• Treatment of Recurrent Clostridium Difficile Infection With RBX7455CompletedNCT02981316Phase 1
• AssessmeNT of the Incidence of Clostridium Difficile Infections in Hospitalized Patients on Antibiotic TrEatmentCompletedNCT02896244
• MET-2 Clinical Study for Recurrent Clostridium Difficile Infection (CDI)CompletedNCT02865616Phase 1
• SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent RecurrenceCompletedNCT02830542Phase 1

← Clostridium Infections overview